Gensumycin (Gentamicin)

What Is Gensumycin and What Is It Used For?

Gensumycin is an aminoglycoside antibiotic containing gentamicin sulfate. It is used to treat serious bacterial infections affecting the lungs, urinary tract, abdomen, and heart valves (endocarditis) in both adults and children. It is administered by injection in hospital settings.

Gensumycin belongs to the aminoglycoside class of antibiotics, a group of powerful antimicrobial agents that have been used in clinical medicine since the 1960s. The active substance, gentamicin, works by binding to the 30S ribosomal subunit of susceptible bacteria. This binding disrupts normal protein synthesis within the bacterial cell, leading to misread genetic code, production of faulty proteins, and ultimately bacterial cell death. This mechanism makes gentamicin a bactericidal antibiotic, meaning it kills bacteria rather than simply stopping their growth.

Gentamicin demonstrates concentration-dependent killing, which means that higher peak concentrations relative to the minimum inhibitory concentration (MIC) of the infecting organism result in more effective bacterial killing. It also exhibits a significant post-antibiotic effect (PAE), meaning that bacterial growth remains suppressed even after drug levels fall below the MIC. These pharmacodynamic properties have influenced modern dosing strategies, with many centres now using once-daily (extended-interval) dosing rather than traditional multiple daily doses.

The spectrum of activity of gentamicin is primarily directed against Gram-negative aerobic bacteria, including Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Proteus species, Serratia species, and Enterobacter species. It also has activity against certain Gram-positive organisms, most notably Staphylococcus aureus. Gentamicin is frequently used in combination with other antibiotics, particularly beta-lactams, to achieve synergistic bactericidal activity, especially in serious infections such as bacterial endocarditis.

Common clinical indications

Gensumycin is indicated for the treatment of a range of serious infections where the causative organism is known or suspected to be susceptible to gentamicin. These indications include:

• Severe respiratory tract infections – including hospital-acquired pneumonia and ventilator-associated pneumonia caused by susceptible Gram-negative organisms
• Complicated urinary tract infections – including pyelonephritis and urosepsis, particularly when caused by multi-resistant organisms
• Intra-abdominal infections – including peritonitis and biliary tract infections, typically used in combination with other antibiotics
• Bacterial endocarditis – inflammation of the heart valves, where gentamicin is used synergistically with penicillins or vancomycin
• Septicaemia (blood poisoning) – empirical treatment of severe sepsis, often as part of combination therapy
• Bone and joint infections – osteomyelitis and septic arthritis caused by susceptible organisms

What Should You Know Before Taking Gensumycin?

Do not use Gensumycin if you are allergic to gentamicin or other aminoglycoside antibiotics. Tell your doctor about any hearing problems, kidney disease, myasthenia gravis, or if you are pregnant. Blood monitoring and kidney function tests are required throughout treatment.

Contraindications

You must not receive Gensumycin if:

• You are allergic to gentamicin sulfate or any of the other ingredients in this medicine
• You are allergic to other aminoglycoside antibiotics (such as tobramycin, amikacin, or streptomycin), as cross-sensitivity between aminoglycosides is well documented

Aminoglycoside hypersensitivity can manifest as skin rashes, urticaria, or, in rare cases, anaphylaxis. If you have experienced any allergic reaction to an aminoglycoside antibiotic in the past, it is critical to inform your healthcare provider before treatment with Gensumycin begins.

Warnings and Precautions

Before receiving Gensumycin, tell your doctor, pharmacist, or nurse if any of the following apply to you or your family:

• Ototoxicity history: You or a family member has experienced hearing damage from medications, including symptoms such as tinnitus (ringing in the ears), balance problems (associated with dizziness, nausea, and blurred vision), hearing loss, or deafness
• Mitochondrial mutations: You or a family member on your mother’s side has a mitochondrial mutation (a genetic condition) or hearing loss caused by antibiotics. Certain mitochondrial DNA mutations, particularly the m.1555A>G mutation, can dramatically increase the risk of aminoglycoside-induced hearing loss. Your doctor may recommend genetic testing before starting Gensumycin
• Kidney impairment: You have reduced kidney function, as gentamicin is almost exclusively excreted by the kidneys. Impaired renal function leads to drug accumulation and increases the risk of nephrotoxicity and ototoxicity
• Advanced age: Older adults are at higher risk of aminoglycoside toxicity due to age-related decline in kidney function
• Dehydration: Inadequate fluid intake increases the risk of drug accumulation and toxicity
• Neuromuscular disorders: Including myasthenia gravis, as aminoglycosides can worsen muscle weakness and potentially cause neuromuscular blockade

Pregnancy and Breastfeeding

If you are pregnant, breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before receiving Gensumycin.

Pregnancy: The use of Gensumycin is not recommended during pregnancy. Gentamicin can cross the placenta and may cause harm to the developing fetus. Cases of irreversible bilateral congenital deafness have been reported in children whose mothers received aminoglycoside antibiotics, including streptomycin, during pregnancy. The eighth cranial nerve (vestibulocochlear nerve) of the fetus is particularly vulnerable to aminoglycoside-induced damage. Gensumycin should only be used during pregnancy if the potential benefit to the mother clearly outweighs the risk to the fetus, and no safer alternative antibiotic is available.

Breastfeeding: The use of Gensumycin is not recommended during breastfeeding. Small amounts of gentamicin can be detected in breast milk. Although gentamicin is poorly absorbed from the infant’s gastrointestinal tract and is therefore expected to be rapidly inactivated, the potential for effects on the infant’s developing intestinal flora exists. Based on the extensive clinical experience with this class of medication, gentamicin would not be expected to pose a significant risk to the breastfed infant when used appropriately. However, it should only be used if the potential benefits clearly outweigh the risks.

Driving and Operating Machinery

Side effects of Gensumycin such as dizziness and balance disturbances may affect your ability to drive or operate machinery. You should not drive or engage in activities requiring alertness until you know how Gensumycin affects you. Discuss with your healthcare provider if you have concerns.

How Does Gensumycin Interact with Other Drugs?

Gensumycin interacts with several medications that can increase the risk of kidney damage or hearing loss. Key interactions include loop diuretics (furosemide), amphotericin B, cisplatin, ciclosporin, and cephalosporin antibiotics. Always inform your healthcare provider about all medications you are taking.

Drug interactions with gentamicin are clinically significant because many of the interacting drugs share similar toxicity profiles, particularly regarding the kidneys and auditory system. When two or more nephrotoxic or ototoxic drugs are used concurrently, the risk of toxicity is additive or even synergistic. Your healthcare provider will carefully consider all concomitant medications before prescribing Gensumycin and may adjust dosing, increase monitoring, or choose an alternative antibiotic.

Other aminoglycoside interactions

Gensumycin should not be administered concurrently with other aminoglycosides (such as tobramycin, amikacin, or neomycin) or with other known ototoxic or nephrotoxic agents unless clinically necessary and under strict monitoring. The combination of two nephrotoxic drugs substantially increases the risk of acute kidney injury.

Additionally, gentamicin can interact with neuromuscular blocking agents (used during anaesthesia), potentially prolonging the duration of neuromuscular blockade. Anaesthesiologists should be informed if a patient is receiving gentamicin therapy.

What Is the Correct Dosage of Gensumycin?

The dosage of Gensumycin is determined by your doctor based on your body weight, kidney function, and the severity of the infection. Typical adult dosage is 3–5 mg/kg/day given as once-daily dosing or divided into multiple doses. Therapeutic drug monitoring guides dose adjustments.

Gensumycin dosing is highly individualised and depends on several factors including the patient’s weight, renal function, the site and severity of infection, and the susceptibility of the causative organism. Two main dosing strategies are used in clinical practice:

Therapeutic Drug Monitoring (TDM)

Therapeutic drug monitoring is a critical component of gentamicin therapy. Blood samples are taken at specific times to measure drug concentrations and ensure they remain within the therapeutic window. For once-daily dosing, trough levels (taken just before the next dose) are typically targeted at less than 1 mg/L. For traditional dosing, peak levels (1 hour post-dose) of 5–10 mg/L and trough levels of less than 2 mg/L are generally targeted, depending on the infection type and institutional protocols.

Your healthcare provider will adjust subsequent doses based on these measurements. TDM is particularly important in patients with changing renal function, the critically ill, neonates, and the elderly.

Overdose

Excessive doses of Gensumycin can cause dizziness, hearing impairment, and seizures. In the event of an overdose, your healthcare team will take appropriate measures, which may include haemodialysis or peritoneal dialysis to remove gentamicin from the blood. Supportive care and close monitoring of renal and auditory function are essential following an overdose.

What Are the Side Effects of Gensumycin?

The most clinically significant side effects of Gensumycin are kidney damage (nephrotoxicity) and hearing/balance damage (ototoxicity). Common side effects include dizziness, nausea, hearing changes, skin reactions, and elevated creatinine. Seek immediate medical attention for signs of allergic reaction, hearing loss, or decreased urine output.

Like all medicines, Gensumycin can cause side effects, although not everybody experiences them. Aminoglycosides have a narrow therapeutic index, meaning the difference between an effective dose and a toxic dose is relatively small. This is why therapeutic drug monitoring and regular clinical assessments are essential during treatment.

Understanding nephrotoxicity

Kidney damage from gentamicin typically manifests as a rise in serum creatinine and blood urea nitrogen (BUN), reduced urine output, or the presence of protein or cells in the urine. Nephrotoxicity is usually reversible if detected early and the drug is discontinued or the dose is adjusted. Risk factors for nephrotoxicity include pre-existing renal impairment, dehydration, concurrent use of other nephrotoxic drugs, prolonged treatment duration, and high trough drug levels.

Understanding ototoxicity

Hearing and balance damage from gentamicin can affect either the cochlea (hearing) or the vestibular system (balance), or both. Vestibular toxicity is more commonly reported with gentamicin than cochlear toxicity. Symptoms may include tinnitus, a sensation of fullness in the ears, vertigo, unsteadiness, and progressive hearing loss. Unlike nephrotoxicity, ototoxicity may be irreversible, making early detection critical. Patients with mitochondrial DNA mutations (particularly m.1555A>G) are at dramatically increased risk of aminoglycoside-induced hearing loss, even from a single dose.

How Should You Store Gensumycin?

Gensumycin does not require special storage conditions. Keep it out of the sight and reach of children. Do not use after the expiry date on the label. Prepared solutions are for single use only and should be used within 12 hours.

This medicine does not require any special storage conditions. Store it at the temperature recommended by your healthcare facility’s pharmacy. Like all medicines, keep Gensumycin out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the label and carton after “EXP”. The expiry date refers to the last day of that month. Once the vial has been opened and the solution prepared, it is for single use only and must be used within 12 hours. Any unused solution should be discarded appropriately.

Do not dispose of medicines in wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer need. These measures help to protect the environment.

What Does Gensumycin Contain?

Gensumycin contains gentamicin sulfate as the active substance (equivalent to 40 mg gentamicin per mL). Inactive ingredients include sodium chloride, sulfuric acid/sodium hydroxide (for pH adjustment), and water for injections.

Each millilitre of Gensumycin injection solution contains gentamicin sulfate equivalent to 40 mg gentamicin. The medicine is supplied in 2 mL glass vials, available in packs of 5 vials (5 × 2 mL).

Active substance

Gentamicin sulfate – a water-soluble salt of gentamicin, an aminoglycoside antibiotic originally derived from Micromonospora purpurea. Gentamicin is a mixture of related aminoglycoside compounds, predominantly gentamicin C1, C1a, and C2.

Inactive ingredients (excipients)

• Sodium chloride – used to make the solution isotonic (compatible with body fluids)
• Sulfuric acid and/or sodium hydroxide – used to adjust the pH of the solution to an appropriate level
• Water for injections – the solvent used to prepare the injectable solution

The solution appears as a clear to slightly opalescent, colourless to pale yellow liquid. Do not use the medicine if the solution is cloudy, contains visible particles, or if the container is damaged.

Marketing authorisation holder and manufacturer

The marketing authorisation for Gensumycin is held by Amdipharm Limited, Dublin, Ireland. The medicine is manufactured by Famar Health Care Services Madrid S.A.U. (Spain) and CENEXI HSC (France).